Tuesday, March 12, 2013

MERCK - DSMB RECOMMENDS TO CONTINUE IMPROVE-IT TRIAL TILL COMPLETION (SEPTEMBER 2014)

Merck announced today that as per planned interim analysis, the Data Safety monitoring board has recommended that the IMPROVE-IT trial should continue till completion.  The DSMB could have discontinued the trial only if in the interim analysis it is found that Vytorin is either superior or inferior to Zocor (comparator arm). With the trial progressing to completion it ensures that Vytorin is atleast as safe or efficacious as Zocor. The final data may now be expected in early 2015. The announcement removes the overhang on the stock price, as investors were cautious about the interim analysis. A negative outcome (vytorin inferior to zocor) would have killed this franchise (Vytorin and Zetia - $4b in sales)  almost imminently. Now we can expect the Vytorin franchise to continue on its trajectory and thus a potential risk is mitigated.




Enter your email address:


Delivered by FeedBurner